Trial Profile
Efficacy and safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2011
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms EFALUPUS
- 07 Jul 2011 New trial record